WO2021152575A1 - Compositions for hemorrhoid treatment - Google Patents
Compositions for hemorrhoid treatment Download PDFInfo
- Publication number
- WO2021152575A1 WO2021152575A1 PCT/IL2021/050059 IL2021050059W WO2021152575A1 WO 2021152575 A1 WO2021152575 A1 WO 2021152575A1 IL 2021050059 W IL2021050059 W IL 2021050059W WO 2021152575 A1 WO2021152575 A1 WO 2021152575A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- liquid composition
- amount
- present
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- 208000014617 hemorrhoid Diseases 0.000 title claims abstract description 20
- 229930003827 cannabinoid Natural products 0.000 claims abstract description 23
- 239000003557 cannabinoid Substances 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- 239000004744 fabric Substances 0.000 claims abstract description 19
- 239000005526 vasoconstrictor agent Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000013543 active substance Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 72
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 37
- 229950011318 cannabidiol Drugs 0.000 claims description 37
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 37
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 37
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 37
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
- 241000208680 Hamamelis mollis Species 0.000 claims description 22
- 229940118846 witch hazel Drugs 0.000 claims description 22
- 229920006037 cross link polymer Polymers 0.000 claims description 18
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical group CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 15
- 229960001802 phenylephrine Drugs 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 14
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 13
- 230000003444 anaesthetic effect Effects 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 13
- 229960001896 pramocaine Drugs 0.000 claims description 13
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 claims description 13
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 11
- 229940075529 glyceryl stearate Drugs 0.000 claims description 10
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000004909 Moisturizer Substances 0.000 claims description 7
- 239000003908 antipruritic agent Substances 0.000 claims description 7
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 7
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 claims description 7
- 230000001333 moisturizer Effects 0.000 claims description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 6
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 6
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 6
- 241000723346 Cinnamomum camphora Species 0.000 claims description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 6
- 239000000730 antalgic agent Substances 0.000 claims description 6
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 6
- 229960000846 camphor Drugs 0.000 claims description 6
- 229930008380 camphor Natural products 0.000 claims description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 6
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 6
- 239000008633 juniper tar Substances 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 229920000058 polyacrylate Polymers 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229940072029 trilaureth-4 phosphate Drugs 0.000 claims description 6
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical class [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 5
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 claims description 4
- -1 Alkyl Glucoside Chemical class 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 229940073669 ceteareth 20 Drugs 0.000 claims description 4
- 229940074979 cetyl palmitate Drugs 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims description 4
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 3
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 3
- KIOWXTOCDZJCBM-UHFFFAOYSA-N 2-docosoxyethyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCOCCOC(=O)C(C)=C KIOWXTOCDZJCBM-UHFFFAOYSA-N 0.000 claims description 3
- JUFHABKBWMZXKL-UHFFFAOYSA-N 2-dodecoxyethyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCOCCOP(O)(O)=O JUFHABKBWMZXKL-UHFFFAOYSA-N 0.000 claims description 3
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 claims description 3
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 3
- CYUZOYPRAQASLN-UHFFFAOYSA-N 3-prop-2-enoyloxypropanoic acid Chemical compound OC(=O)CCOC(=O)C=C CYUZOYPRAQASLN-UHFFFAOYSA-N 0.000 claims description 3
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001263 FEMA 3042 Substances 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 claims description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 claims description 3
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims description 3
- 229940110830 beheneth-25 methacrylate Drugs 0.000 claims description 3
- 229960005274 benzocaine Drugs 0.000 claims description 3
- 235000014121 butter Nutrition 0.000 claims description 3
- 229940083913 c14-22 alcohols Drugs 0.000 claims description 3
- 229940105847 calamine Drugs 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 229940064273 ceteareth-22 Drugs 0.000 claims description 3
- 229940013617 ceteth-20 phosphate Drugs 0.000 claims description 3
- 229960001747 cinchocaine Drugs 0.000 claims description 3
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims description 3
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229960002228 diperodon Drugs 0.000 claims description 3
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 claims description 3
- 229940047647 disodium ethylene dicocamide peg-15 disulfate Drugs 0.000 claims description 3
- 229960000735 docosanol Drugs 0.000 claims description 3
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000385 dyclonine Drugs 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- 229960004842 ephedrine sulfate Drugs 0.000 claims description 3
- 229960005139 epinephrine Drugs 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 229930182478 glucoside Natural products 0.000 claims description 3
- 229910052864 hemimorphite Inorganic materials 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 3
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 claims description 3
- 229940048848 lauryl glucoside Drugs 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 238000010979 pH adjustment Methods 0.000 claims description 3
- 229940101267 panthenol Drugs 0.000 claims description 3
- 235000020957 pantothenol Nutrition 0.000 claims description 3
- 239000011619 pantothenol Substances 0.000 claims description 3
- 229940100460 peg-100 stearate Drugs 0.000 claims description 3
- 239000003961 penetration enhancing agent Substances 0.000 claims description 3
- 229950007049 phenacaine Drugs 0.000 claims description 3
- QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229940113124 polysorbate 60 Drugs 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229950011392 sorbitan stearate Drugs 0.000 claims description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 3
- 229920002258 tannic acid Polymers 0.000 claims description 3
- 229940033123 tannic acid Drugs 0.000 claims description 3
- 235000015523 tannic acid Nutrition 0.000 claims description 3
- 229960002372 tetracaine Drugs 0.000 claims description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 235000014692 zinc oxide Nutrition 0.000 claims description 3
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims description 3
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 229940072106 hydroxystearate Drugs 0.000 claims description 2
- 239000010460 hemp oil Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229940065144 cannabinoids Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 4
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 4
- 229940036350 bisabolol Drugs 0.000 description 4
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229940068977 polysorbate 20 Drugs 0.000 description 4
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 3
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- 235000009120 camo Nutrition 0.000 description 3
- 235000005607 chanvre indien Nutrition 0.000 description 3
- 229960004242 dronabinol Drugs 0.000 description 3
- 239000011487 hemp Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- JAAJERPNGYESPY-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]ethanol 1-phenoxyethanol Chemical compound C(COCCOCCO)O.O(C1=CC=CC=C1)C(C)O JAAJERPNGYESPY-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000208681 Hamamelis virginiana Species 0.000 description 1
- 241000665848 Isca Species 0.000 description 1
- 229920000433 Lyocell Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- NENOAJSZZPODGJ-OIMNJJJWSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octanoate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NENOAJSZZPODGJ-OIMNJJJWSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4266—Natural fibres not provided for in group D04H1/425
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- compositions for the treatment of hemorrhoids are provided herein.
- Hemorrhoids are swollen veins in the anus and lower rectum, which lead to itching, irritation, pain, swelling and/or bleeding. Hemorrhoids can be external, in the anal area, or internal, inside the rectum.
- Hemorrhoids are caused by the bulging, stretching or swelling of veins in the anorectal area.
- the underlying cause of hemorrhoids may be straining while passing bowel movements, constipation, pregnancy, obesity, or lifting heavy weights.
- compositions in the form of wet wipes comprising active agents to treat hemorrhoids.
- the compositions comprise a fabric, a cannabinoid and at least one additional agent, the agent preferably selected from the group consisting of a vasoconstrictor and an astringent.
- a wet wipe comprising a fabric, a cannabinoid and at least one additional agent the agent preferably selected from the group consisting of a vasoconstrictor and an astringent.
- wet wipes comprise a fabric and a liquid composition embedded in the wet wipe.
- the liquid compositions comprise a cannabinoid, in combination with at least one additional active ingredient, in the form of a wet wipe.
- the active ingredient is an astringent or a vasoconstrictor.
- the active ingredient is an anesthetic.
- the astringent may be witch hazel.
- the vasoconstrictor may be phenylephrine.
- the anesthetic is pramoxine.
- cannabinoids will act synergistically with at least one additional active ingredient as described herein to provide an effect to enhance treatment of hemorrhoids.
- Witch hazel is an astringent formed as an extract from the plant Hamamelis virginiana.
- Astringents are agents which cause contraction of human tissue when applied. Additional or alternative astringents which may be used include, but are not limited to: calamine and tannic acid.
- Phenylephrine is a vasoconstrictor which acts as an ai -adrenergic receptor activator.
- Vasoconstrictors are agents which reduce blood flow by narrowing blood vessels. When applied locally, for example, topically or rectally, vasoconstrictors can treat affected areas by limiting blood flow to the applied area.
- vasoconstrictors which may be used include: ephedrine sulfate, epinephrine, or salts thereof.
- Pramoxine is an anesthetic and antipruritic which may be used for topical, rectal and/or vaginal administration. Local administration of an anesthetic reduces sensation of pain and/or itching at the site of local administration.
- anesthetics which may be used include, but are not limited to camphor, juniper tar, menthol, diperodon, phenacaine, benzocaine, benzyl alcohol, dibucaine, dyclonine, lidocaine, and tetracaine, and salts thereof.
- an astringent for example, witch hazel, may be present in an amount between 10% and 70% of the liquid composition.
- the astringent may be present in an amount between 40% and 60% of the liquid composition.
- the astringent is present in an amount of 50% of the liquid composition.
- a vasoconstrictor for example phenylephrine, may be present in an amount between about 0.1% and about 1% of the liquid composition.
- the vasoconstrictor may be present in an amount between 0.2% and 0.5% of the liquid composition.
- the vasoconstrictor may be present in an amount of 0.25% of the liquid composition.
- an anesthetic for example pramoxine
- an anesthetic may be present in an amount between about 0.1% and about 2% of the liquid composition.
- the anesthetic may be present in an amount between 0.5% and 1.5% of the liquid composition.
- the anesthetic may be present in an amount of 1% of the liquid composition.
- a cannabinoid is a chemical compound that acts on cannabinoid receptors in cells in mammals, including in humans.
- Cannabinoids can be manufactured synthetically or obtained from various parts of the genus Cannabis, in particular, from the species Cannabis Sativa.
- Two preferred cannabinoids according to various embodiments are (-)-trans-A 9 - tetrahydrocannabinol, and/or isomers thereof (THC) and cannabidiol (CBD).
- a cannabinoid may be in the form of hemp oil.
- a cannabinoid may be in the form of cannabis oil or isolate.
- Compositions described herein may comprise one cannabinoid or multiple cannabinoids, such as a combination of CBD and THC.
- Cannabinoids may be synthetically produced or isolated from plants.
- a cannabinoid may be present in an amount between about 0.01% and about 10% of the liquid composition.
- a cannabinoid may be present in an amount between about 0.1% and 1% of the liquid composition.
- the cannabinoid may be present in an amount between 0.25% and 0.5% of the liquid composition, preferably 0.35% of the composition.
- Additional active ingredients may be selected from the group consisting of analgesics, or antipruritic agents. Examples of analgesics and antipruritic agents include camphor, juniper tar and menthol.
- compositions described herein may further comprise at least one inert ingredient.
- the inert ingredient may be selected from the group consisting of: water, a solvent, an emulsifier, an emollient, a moisturizer, a pH adjustment agent, a polymer, a humectant, an occlusive agent, a preservative, a thickener, an anti-irritation agent, a conditioning agent, a buffer, a vitamin, an extract, a natural oil, a wax, a penetration enhancer, a peptide, a sugar derivative, a fatty acid, a fatty alcohol, a silicone, a polyethyl-glycol, a fragrance, a pigment, an ester, a triglyceride, a butter, hyaluronic acid, and an absorbing powder.
- the preservative may be selected from the group consisting of: a parahydroxybenzoic acid, methylparaben, propylparaben, Benzyl Alcohol, Phenoxyethanol, Ethylhexylglycerin, Octanediol, Hexanediol, Pentandiol, Sorbitan Caprylate, capralyl glycol, caprylhydroxamic acid, Phenoxyethanol Triethylene glycol, sodium benzoate, and Bronopol.
- the preservative is Phenoxyethanol Triethylene glycol.
- the liquid compositions further comprise a moisturizer.
- the moisturizer may be, for example, aloe barbadensis leaf juice or panthenol.
- the liquid compositions further comprise a humectant.
- the humectant may be glycerin.
- the humectant may be present in the liquid composition in an amount of between 1% and 5%, preferably 3%.
- the liquid composition may be an emulsion, such as an oil in water emulsion.
- an emulsion such as an oil in water emulsion.
- liquid compositions may be prepared with at least one emulsifier.
- the emulsifier is selected from the group consisting of: Acrylates/ C10- 30 alkyl acrylate crosspolymer (PemulenTM Tr-2); Sodium Acrylates/C 10-30 Alkyl Acrylates Crosspolymers (Cosmedia® SP); Trilaureth-4 Phosphate (Hostaphat® KL 340) and Cetearyl Isononanoate (and) Ceteareth-20 (and) Cetearyl Alcohol (and) Glyceryl Stearate (and) Glycerin (and) Ceteareth-12 (and) Cetyl Palmitate (Emulgade® CM).
- the emulsifier is selected from the group consisting of: C14-22 Alcohols (and) C12-20 Alkyl Glucoside (MONTANOV L); Arachidyl Alcohol (and) Behenyl Alcohol (and) Arachidyl Glucoside (MONTANOV 202); Polyacrylate Crosspolymer-6 (SEPIMAX ZEN); Microcrystalline cellulose and cellulose gum (AVICEL PC 611); Sucrose Palmitate (Sisterna PS750-C); Aqua, Sucrose Laurate, Alcohol (Sisterna L70-C); CETEARYL ALCOHOL AND CETETH - 20 PHOSPHATE AND DICETYL PHOSPHAT (CRODAFOS CS20 ACID); Potassium Laureth- 1 Phosphate (Dermalcare® MAP L-213/K); Hydroxy ethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer (and) Isohexadecane (and) Polysorbate 60 (
- the ratio in the wet wipes between fabric and liquid composition is between 1:2 and 1:4, preferable 1:3.
- the wet wipes according embodiments may be individually packaged in a single-wipe packet.
- wipes may be packaged in a container, such as a bottle or resealable bag.
- the wipes may be packaged in a flow pack so that when a first wipe is removed, a subsequent wipe is partially advanced to the opening of the flow pack.
- certain embodiments relate to methods for treatment of hemorrhoids comprising applying to an affected are of a person in need thereof a wet wipe comprising a comprise a fabric, a cannabinoid and at least one additional agent.
- the hemorrhoids may be external hemorrhoids.
- the composition may be applied between once and 6 times daily.
- the composition may be applied after the patient in need thereof has a bowel movement.
- wet wipes described herein are advantageous in that they combine ingredients that are water soluble, such as astringent agents, vasoconstrictors and/or anesthetic agents, in combination with active cannabinoids which are not soluble in water.
- astringent agents such as astringent agents, vasoconstrictors and/or anesthetic agents
- active cannabinoids which are not soluble in water.
- Example 1A Preparation of wet wipes with CBD and witch hazel.
- a liquid for preparing wet wipes is prepared according to the ingredients in Table 1.
- Pemulen TR-2 is provided by Lubrizol Corp. Wickliffe, Ohio, USA. Iscaguard is provided by ISCA UK Ltd., United Kingdom. Cannabidiol is Hemp-derived CBD Isolate, having a purity of >97%. Glycerin is added to Acrylates/ C 10-30 alkl acrylate crosspolymer, and homogenized until a clear gel is obtained without lumps. NaOH solution is added while mixing until a pH of 6.0-6.5 is obtained. Witch Hazel is then added.
- CBD is added to hemp oil, which is heated to 40°C, until CBD is completely dissolved.
- the hemp oil is then added to the witch hazel vessel.
- a whitish/ translucent liquid is formed.
- Example IB Preparation of wet wipes with CBD, Witch Hazel, and Phenylephrine HC1
- a liquid for preparing wet wipes is prepared according to the ingredients in Table 2.
- Table 2 Cannabidiol is Hemp-derived CBD Isolate, having a purity of >97%.
- Glycerin is added to Acrylates/ C 10-30 alkyl acrylate crosspolymer, and homogenized until a clear gel is obtained without lumps. NaOH solution is added while mixing until a pH of 6.0-6.5 is obtained. Witch Hazel is then added, then phenylephrine HC1. In a separate vessel CBD is added to hemp oil, which is heated to 40°C, until CBD is completely dissolved. The hemp oil is then added to the witch hazel vessel. Bisabolol, Polysorbate-20 and Iscaguard and homogenized for two minutes.
- Example 1C Preparation of wet wipes with CBD and witch hazel
- a liquid for preparing wet wipes is prepared according to the ingredients in Table 3.
- Cannabidiol is Hemp-derived CBD Isolate, having a purity of >97%.
- Trilaureth-4 Phosphate is obtained as Hostaphat® KL 340 by Clairant International
- CBD is added to hemp oil, which is heated to 40°C, until CBD is completely dissolved.
- the hemp oil is then added to the aqueous mixture.
- Trilaureth-4 Phosphate, Bisabolol, Polysorbate-20 and Iscaguard are added and homogenized for 10 minutes.
- a whitish/ translucent liquid is formed.
- Example ID Preparation of wet wipes with CBD and witch hazel Preparation of wet wipes with CBD and witch hazel.
- a liquid for preparing wet wipes is prepared according to the ingredients in Table 4.
- Cosmedia® SP is a trade name of BASF, Ludwigshafen, Germany, relating to the product Sodium polyacrylate, Sodium Acrylates/C 10-30 Alkyl Acrylates Crosspolymers. Glycerin is added to Cosmedia® SP and homogenized until a clear gel is obtained without lumps. Witch hazel is then added. In a separate vessel CBD is added to hemp oil, which is heated to 40°C, until CBD is completely dissolved. The hemp oil is then added to the witch hazel vessel. Bisabolol, Polysorbate-20 and Iscaguard are then added and homogenized for two minutes.
- a whitish/ translucent liquid is formed.
- Example 2A Preparation of wet wipes with CBD, Phenylephrine HC1, and Pramoxine HC1
- a liquid for preparing wet wipes is prepared according to the ingredients in Table 5.
- Table 5 Table 5:
- Emulgade® CM is a trade name of BASF, Ludwigshafen, Germany, relating to the product: Cetearyl Isononanoate (and) Ceteareth-20 (and) Cetearyl Alcohol (and) Glyceryl Stearate (and) Glycerin (and) Ceteareth-12 (and) Cetyl Palmitate. NatrosolTM is available from Ashland Global Specialty Chemicals Inc., Covington, Kentucky, USA.
- Emulgade® CM hemp oil
- cannabidiol tocopheryl acetate
- Iscaguard® is added and mixed to form a clear oil.
- the cannabidiol containing solution is then mixed with the aqueous solution with moderate mixing to form a whitish lotion with low viscosity.
- Example 2B Preparation of wet wipes with CBD, Phenylephrine HC1, and Pramoxine HC1
- a liquid for preparing wet wipes is prepared according to the ingredients in Table 6.
- Table 6 Water and the subsequent 6 ingredients are added, one by one, and mixed to form a clear solution.
- Emulgade® CM and trilaureth-4 phosphate are mixed, then added to the aqueous solution.
- hemp oil, cannabidiol are added and mixed to form a clear oil.
- the cannabidiol containing solution is then mixed with the aqueous solution with moderate mixing.
- the tocopheryl acetate and Iscaguard® preservative are added to form a whitish lotion with low viscosity.
- Example 3 Incorporation of liquid into wet wipes.
- Liquids for wet wipes is prepared according to Examples 1A-D and 2A-B.
- Fabric used for the manufacture of wet wipes is optionally non-woven fabric.
- the non-woven fabric is spun-laced fabric.
- the wet wipes are made from one of or a combination of polyester, polypropylene, viscose, Tencel, wood pulp, or cotton.
- the wet wipe fabric comprises polyester and viscose.
- the liquid is introduced onto a fabric and the combined product has a ratio of 1:2- 1:4, fabric to liquid.
- Fabric is shortly thereafter introduced into a sterile receptacle comprising the liquid.
- the wipes are then cut and folded and packaged into a sealed, waterproof packaging to avoid evaporation or contamination.
- a wet wipe composition comprising a fabric, and a liquid composition, the liquid composition comprising a cannabinoid and at least one additional active agent selected from the group consisting of a vasoconstrictor and an astringent.
- the composition further comprising an anesthetic.
- the astringent is selected from the group consisting of: witch hazel, calamine and tannic acid.
- the astringent is witch hazel, and is present in an amount of between 10% and 70% of the liquid composition.
- the witch hazel is present in an amount of between 40% and 60% of the liquid composition, optionally, in an amount of 50% of the liquid composition.
- the vasoconstrictor is selected from the group consisting of phenylephrine, ephedrine sulfate, epinephrine, or salts thereof.
- the vacoconstrictor is phenylephrine, and is present in an amount between 0.1% and 1% of the liquid composition.
- phenylephrine is present in an amount between 0.2% and 0.5% of the liquid composition.
- phenylephrine is present in an amount of 0.25% of the liquid composition.
- the anesthetic is selected from the group consisting of: pramoxine, camphor, juniper tar, menthol, diperodon, phenacaine, benzocaine, benzyl alcohol, dibucaine, dyclonine, lidocaine, and tetracaine, and salts thereof.
- the anesthetic is pramoxine, and is present in an amount between 0.1% and 2% of the liquid composition.
- the pramoxine is present in an amount between 0.5% and 1.51% of the liquid composition.
- the pramoxine is present in an amount of 1% of the liquid composition.
- the cannabinoid is cannabidiol (CBD).
- CBD is present in an amount between 0.01% and 10% of the liquid composition, in an amount between 0.1% and 1% of the liquid composition, in an amount between 0.25% and 0.5% of the liquid composition, or in an amount of 0.35% of the liquid composition.
- the composition further comprises an analgesic or antipruritic agent.
- the analgesic or antipruritic agent is selected from the group consisting of: camphor, juniper tar and menthol.
- the composition further comprises one or more of the following ingredients: water, a solvent, an emulsifier, an emollient, a moisturizer, a pH adjustment agent, a polymer, a humectant, an occlusive agent, a preservative, a thickener, an anti-irritation agent, a conditioning agent, a buffer, a vitamin, an extract, a natural oil, a wax, a penetration enhancer, a peptide, a sugar derivative, a fatty acid, a fatty alcohol, a silicone, a polyethyl-glycol, a fragrance, a pigment, an ester, a triglyceride, a butter, hyaluronic acid, and an absorbing powder.
- water a solvent, an emulsifier, an emollient, a moisturizer, a pH adjustment agent, a polymer, a humectant, an occlusive agent, a preservative, a thickener
- the moisturizer is selected from the group consisting of aloe barbadensis leaf juice and panthenol.
- the humectant is glycerin.
- the liquid is an oil in water emulsion.
- the emulsifier is selected from the group consisting of: Acrylates/ C 10-30 alkyl acrylate crosspolymer (PemulenTM Tr-2); Sodium Acrylates/C 10-30 Alkyl Acrylates Crosspolymers (Cosmedia® SP); Trilaureth-4 Phosphate (Hostaphat® KL 340) and Cetearyl Isononanoate (and) Ceteareth- 20 (and) Cetearyl Alcohol (and) Glyceryl Stearate (and) Glycerin (and) Ceteareth-12 (and) Cetyl Palmitate (Emulgade® CM); C14-22 Alcohols (and) C12-20 Alkyl Glucoside (MONTANOV L); Arachidyl Alcohol (and) C12-20
- the ratio between fabric and liquid composition is between 1:2 and 1:4.
- the ratio between fabric and liquid composition is 1:3.
- Further embodiments relate to a method for treatment of hemorrhoids comprising applying to an affect area of a subject in need thereof, a wet wipe as described above.
- the subject suffers from an external hemorrhoid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Textile Engineering (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Described herein are compositions in the form of wet wipes comprising active agents to treat hemorrhoids. The compositions comprise a fabric, a cannabinoid and at least one additional agent, the agent preferably selected from the group consisting of a vasoconstrictor and an astringent. Additionally described herein are methods for treating hemorrhoids comprising applying to an affected area of a person in need thereof a wet wipe comprising a fabric, a cannabinoid and at least one additional agent the agent preferably selected from the group consisting of a vasoconstrictor and an astringent.
Description
COMPOSITIONS FOR HEMORRHOID TREATMENT
CROSS REFERENCE TO RELATED APPLICATIONS
Benefit is claimed to US Provisional Patent Application 62/967,614 filed January 30, 2020; the contents of which is incorporated by reference herein in its entirety.
FIELD
Provided herein are compositions for the treatment of hemorrhoids.
BACKGROUND
Hemorrhoids are swollen veins in the anus and lower rectum, which lead to itching, irritation, pain, swelling and/or bleeding. Hemorrhoids can be external, in the anal area, or internal, inside the rectum.
Hemorrhoids are caused by the bulging, stretching or swelling of veins in the anorectal area. The underlying cause of hemorrhoids may be straining while passing bowel movements, constipation, pregnancy, obesity, or lifting heavy weights.
SUMMARY
Described herein are compositions in the form of wet wipes comprising active agents to treat hemorrhoids. The compositions comprise a fabric, a cannabinoid and at least one additional agent, the agent preferably selected from the group consisting of a vasoconstrictor and an astringent.
Additionally described herein are methods for treating hemorrhoids comprising applying to an affected area of a person in need thereof a wet wipe comprising a fabric, a cannabinoid and at least one additional agent the agent preferably selected from the group consisting of a vasoconstrictor and an astringent.
The foregoing and other objects, features, and advantages will become more apparent from the following detailed description.
DETAILED DESCRIPTION
Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in pharmaceutical sciences can be found in Troy et al. Remington: The Science and Practice of Pharmacy. Published by Lippincott Williams & Wilkins, 2006. In case of conflict, the present specification, including explanations of terms,
will control. In addition, all the materials, methods, and examples are illustrative and not intended to be limiting.
Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The term “comprises” means “includes.” The abbreviation, “e.g.” is derived from the Latin exempli gratia and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.”
As mentioned above, embodiments relate to wet wipes. Wet wipes comprise a fabric and a liquid composition embedded in the wet wipe. The liquid compositions comprise a cannabinoid, in combination with at least one additional active ingredient, in the form of a wet wipe. According to an embodiment, the active ingredient is an astringent or a vasoconstrictor. Optionally, the active ingredient is an anesthetic. The astringent may be witch hazel. The vasoconstrictor may be phenylephrine. According to an embodiment, the anesthetic is pramoxine. Without being bound by theory, it is suggested that cannabinoids will act synergistically with at least one additional active ingredient as described herein to provide an effect to enhance treatment of hemorrhoids.
Witch hazel is an astringent formed as an extract from the plant Hamamelis virginiana. Astringents are agents which cause contraction of human tissue when applied. Additional or alternative astringents which may be used include, but are not limited to: calamine and tannic acid.
Phenylephrine is a vasoconstrictor which acts as an ai -adrenergic receptor activator. Vasoconstrictors are agents which reduce blood flow by narrowing blood vessels. When applied locally, for example, topically or rectally, vasoconstrictors can treat affected areas by limiting blood flow to the applied area.
Additional or alternative vasoconstrictors which may be used include: ephedrine sulfate, epinephrine, or salts thereof.
Pramoxine is an anesthetic and antipruritic which may be used for topical, rectal and/or vaginal administration. Local administration of an anesthetic reduces sensation of pain and/or itching at the site of local administration.
Additional or alternative anesthetics which may be used include, but are not limited to camphor, juniper tar, menthol, diperodon, phenacaine, benzocaine, benzyl alcohol, dibucaine, dyclonine, lidocaine, and tetracaine, and salts thereof.
According to an embodiment, an astringent, for example, witch hazel, may be present in an amount between 10% and 70% of the liquid composition. Optionally, the astringent may be present in an amount between 40% and 60% of the liquid composition. Optionally, the astringent is present in an amount of 50% of the liquid composition.
According to an embodiment, a vasoconstrictor, for example phenylephrine, may be present in an amount between about 0.1% and about 1% of the liquid composition. Optionally, the vasoconstrictor may be present in an amount between 0.2% and 0.5% of the liquid composition. Optionally, the vasoconstrictor may be present in an amount of 0.25% of the liquid composition.
According to an embodiment, an anesthetic, for example pramoxine, may be present in an amount between about 0.1% and about 2% of the liquid composition. Optionally, the anesthetic may be present in an amount between 0.5% and 1.5% of the liquid composition. Optionally, the anesthetic may be present in an amount of 1% of the liquid composition.
A cannabinoid is a chemical compound that acts on cannabinoid receptors in cells in mammals, including in humans. Cannabinoids can be manufactured synthetically or obtained from various parts of the genus Cannabis, in particular, from the species Cannabis Sativa. Two preferred cannabinoids according to various embodiments, are (-)-trans-A9- tetrahydrocannabinol, and/or isomers thereof (THC) and cannabidiol (CBD). Alternatively, a cannabinoid may be in the form of hemp oil. Alternatively, a cannabinoid may be in the form of cannabis oil or isolate. Compositions described herein may comprise one cannabinoid or multiple cannabinoids, such as a combination of CBD and THC. Cannabinoids may be synthetically produced or isolated from plants.
According to an embodiment, a cannabinoid may be present in an amount between about 0.01% and about 10% of the liquid composition. Optionally, a cannabinoid may be present in an amount between about 0.1% and 1% of the liquid composition. Optionally, the cannabinoid may be present in an amount between 0.25% and 0.5% of the liquid composition, preferably 0.35% of the composition.
Additional active ingredients may be selected from the group consisting of analgesics, or antipruritic agents. Examples of analgesics and antipruritic agents include camphor, juniper tar and menthol.
In addition to active ingredients, compositions described herein may further comprise at least one inert ingredient. The inert ingredient may be selected from the group consisting of: water, a solvent, an emulsifier, an emollient, a moisturizer, a pH adjustment agent, a polymer, a humectant, an occlusive agent, a preservative, a thickener, an anti-irritation agent, a conditioning agent, a buffer, a vitamin, an extract, a natural oil, a wax, a penetration enhancer, a peptide, a sugar derivative, a fatty acid, a fatty alcohol, a silicone, a polyethyl-glycol, a fragrance, a pigment, an ester, a triglyceride, a butter, hyaluronic acid, and an absorbing powder.
The preservative may be selected from the group consisting of: a parahydroxybenzoic acid, methylparaben, propylparaben, Benzyl Alcohol, Phenoxyethanol, Ethylhexylglycerin, Octanediol, Hexanediol, Pentandiol, Sorbitan Caprylate, capralyl glycol, caprylhydroxamic acid, Phenoxyethanol Triethylene glycol, sodium benzoate, and Bronopol. Preferably, the preservative is Phenoxyethanol Triethylene glycol.
Optionally the liquid compositions further comprise a moisturizer. The moisturizer may be, for example, aloe barbadensis leaf juice or panthenol.
Optionally, the liquid compositions further comprise a humectant. The humectant may be glycerin. The humectant may be present in the liquid composition in an amount of between 1% and 5%, preferably 3%.
Optionally, the liquid composition may be an emulsion, such as an oil in water emulsion. Without being bound by theory, it is suggested that improved moisturizing of the affected area can be obtained in patients suffering from hemorrhoids using an oil in water emulsion liquid composition in a wet wipe when compared to an aqueous-based wet wipe.
In order to form emulsions, liquid compositions may be prepared with at least one emulsifier. Optionally, the emulsifier is selected from the group consisting of: Acrylates/ C10- 30 alkyl acrylate crosspolymer (Pemulen™ Tr-2); Sodium Acrylates/C 10-30 Alkyl Acrylates Crosspolymers (Cosmedia® SP); Trilaureth-4 Phosphate (Hostaphat® KL 340) and Cetearyl Isononanoate (and) Ceteareth-20 (and) Cetearyl Alcohol (and) Glyceryl Stearate (and) Glycerin (and) Ceteareth-12 (and) Cetyl Palmitate (Emulgade® CM). Optionally, the emulsifier is selected from the group consisting of: C14-22 Alcohols (and) C12-20 Alkyl Glucoside (MONTANOV L); Arachidyl Alcohol (and) Behenyl Alcohol (and) Arachidyl Glucoside (MONTANOV 202); Polyacrylate Crosspolymer-6 (SEPIMAX ZEN); Microcrystalline
cellulose and cellulose gum (AVICEL PC 611); Sucrose Palmitate (Sisterna PS750-C); Aqua, Sucrose Laurate, Alcohol (Sisterna L70-C); CETEARYL ALCOHOL AND CETETH - 20 PHOSPHATE AND DICETYL PHOSPHAT (CRODAFOS CS20 ACID); Potassium Laureth- 1 Phosphate (Dermalcare® MAP L-213/K); Hydroxy ethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer (and) Isohexadecane (and) Polysorbate 60 (SIMULGEL™ INS 100); Glyceryl Stearate Citrate (and) Polyglyceryl-3 Stearate (and) Hydrogenated Lecithin (Heliofeel™); Ceteareth-25 (and) Disodium Ethylene Dicocamide PEG- 15 Disulfate (CERALUTION ES RSPO-MB); Sorbitan Stearate (SPAN 60); Glyceryl Stearate (and) PEG- 100 Stearate (ARLACEL 165 FL); Polyacrylate Crosspolymer- 11 (Aristoflex® Velvet); Ammonium Acryloyldimethyltaurate/ Beheneth-25 Methacrylate Crosspolymer (Aristoflex® BLV); Ammonium Acryloyldimethyltaurate/VP Copolymer; Glyceryl Stearate; (Aristoflex® A VC); (Aristoflex® TAC); Ammonium Acryloyldimethyltaurate/ Carboxy ethyl Acrylate Crosspolymer (Aristoflex® TAC); Acrylates/C 10-30 Alkyl Acrylate Crosspolymer (Carbopol® Ultrez 20 Polymer); Acrylates Copolymer (Carbopol® Aqua SF-1 Polymer); Lauryl Glucoside (and) Polyglyceryl-2 Dipoly hydroxy stearate (and) Glycerin (Eumulgin® VL 75); and CETEARETH-22 (and) PALMETH-2 (EMULPHARMA XL).
Optionally, the ratio in the wet wipes between fabric and liquid composition is between 1:2 and 1:4, preferable 1:3.
The wet wipes according embodiments may be individually packaged in a single-wipe packet. Alternatively, wipes may be packaged in a container, such as a bottle or resealable bag. The wipes may be packaged in a flow pack so that when a first wipe is removed, a subsequent wipe is partially advanced to the opening of the flow pack.
As described herein, certain embodiments relate to methods for treatment of hemorrhoids comprising applying to an affected are of a person in need thereof a wet wipe comprising a comprise a fabric, a cannabinoid and at least one additional agent. Optionally, the hemorrhoids may be external hemorrhoids.
According to an embodiment, the composition may be applied between once and 6 times daily. Optionally the composition may be applied after the patient in need thereof has a bowel movement.
Wet wipes described herein are advantageous in that they combine ingredients that are water soluble, such as astringent agents, vasoconstrictors and/or anesthetic agents, in combination with active cannabinoids which are not soluble in water.
The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the disclosure to the particular features or embodiments described. EXAMPLES
Example 1A. Preparation of wet wipes with CBD and witch hazel.
Pemulen TR-2 is provided by Lubrizol Corp. Wickliffe, Ohio, USA. Iscaguard is provided by ISCA UK Ltd., United Kingdom. Cannabidiol is Hemp-derived CBD Isolate, having a purity of >97%.
Glycerin is added to Acrylates/ C 10-30 alkl acrylate crosspolymer, and homogenized until a clear gel is obtained without lumps. NaOH solution is added while mixing until a pH of 6.0-6.5 is obtained. Witch Hazel is then added.
In a separate vessel CBD is added to hemp oil, which is heated to 40°C, until CBD is completely dissolved. The hemp oil is then added to the witch hazel vessel. Bisabolol, Polysorbate-20 and Iscaguard and homogenized for two minutes.
A whitish/ translucent liquid is formed.
Example IB: Preparation of wet wipes with CBD, Witch Hazel, and Phenylephrine HC1 A liquid for preparing wet wipes is prepared according to the ingredients in Table 2. Table 2:
Cannabidiol is Hemp-derived CBD Isolate, having a purity of >97%.
Glycerin is added to Acrylates/ C 10-30 alkyl acrylate crosspolymer, and homogenized until a clear gel is obtained without lumps. NaOH solution is added while mixing until a pH of 6.0-6.5 is obtained. Witch Hazel is then added, then phenylephrine HC1. In a separate vessel CBD is added to hemp oil, which is heated to 40°C, until CBD is completely dissolved. The hemp oil is then added to the witch hazel vessel. Bisabolol, Polysorbate-20 and Iscaguard and homogenized for two minutes.
A whitish/ translucent liquid is formed. Example 1C: Preparation of wet wipes with CBD and witch hazel
A liquid for preparing wet wipes is prepared according to the ingredients in Table 3.
Cannabidiol is Hemp-derived CBD Isolate, having a purity of >97%. Trilaureth-4 Phosphate is obtained as Hostaphat® KL 340 by Clairant International
Ltd., Switzerland.
In water, glycerin is added to aloe. Witch Hazel is then added and mixed.
In a separate vessel CBD is added to hemp oil, which is heated to 40°C, until CBD is completely dissolved. The hemp oil is then added to the aqueous mixture. Trilaureth-4 Phosphate, Bisabolol, Polysorbate-20 and Iscaguard are added and homogenized for 10 minutes.
A whitish/ translucent liquid is formed.
Example ID: Preparation of wet wipes with CBD and witch hazel Preparation of wet wipes with CBD and witch hazel. A liquid for preparing wet wipes is prepared according to the ingredients in Table 4.
Cosmedia® SP is a trade name of BASF, Ludwigshafen, Germany, relating to the product Sodium polyacrylate, Sodium Acrylates/C 10-30 Alkyl Acrylates Crosspolymers. Glycerin is added to Cosmedia® SP and homogenized until a clear gel is obtained without lumps. Witch hazel is then added.
In a separate vessel CBD is added to hemp oil, which is heated to 40°C, until CBD is completely dissolved. The hemp oil is then added to the witch hazel vessel. Bisabolol, Polysorbate-20 and Iscaguard are then added and homogenized for two minutes.
A whitish/ translucent liquid is formed.
Example 2A: Preparation of wet wipes with CBD, Phenylephrine HC1, and Pramoxine HC1 A liquid for preparing wet wipes is prepared according to the ingredients in Table 5. Table 5:
Emulgade® CM is a trade name of BASF, Ludwigshafen, Germany, relating to the product: Cetearyl Isononanoate (and) Ceteareth-20 (and) Cetearyl Alcohol (and) Glyceryl
Stearate (and) Glycerin (and) Ceteareth-12 (and) Cetyl Palmitate. Natrosol™ is available from Ashland Global Specialty Chemicals Inc., Covington, Kentucky, USA.
Water and the subsequent 8 ingredients are added, one by one, and mixed to form a clear solution. In a separate container, Emulgade® CM, hemp oil, cannabidiol, tocopheryl acetate and Iscaguard® are added and mixed to form a clear oil. The cannabidiol containing solution is then mixed with the aqueous solution with moderate mixing to form a whitish lotion with low viscosity.
Example 2B: Preparation of wet wipes with CBD, Phenylephrine HC1, and Pramoxine HC1
A liquid for preparing wet wipes is prepared according to the ingredients in Table 6. Table 6:
Water and the subsequent 6 ingredients are added, one by one, and mixed to form a clear solution.
Emulgade® CM and trilaureth-4 phosphate are mixed, then added to the aqueous solution.
In a separate container, hemp oil, cannabidiol, are added and mixed to form a clear oil. The cannabidiol containing solution is then mixed with the aqueous solution with moderate mixing. Then the tocopheryl acetate and Iscaguard® preservative are added to form a whitish lotion with low viscosity.
Example 3: Incorporation of liquid into wet wipes.
Liquids for wet wipes is prepared according to Examples 1A-D and 2A-B.
Fabric used for the manufacture of wet wipes is optionally non-woven fabric. Optionally, the non-woven fabric is spun-laced fabric. Optionally, the wet wipes are made from one of or a combination of polyester, polypropylene, viscose, Tencel, wood pulp, or cotton. Optionally, the wet wipe fabric comprises polyester and viscose.
The liquid is introduced onto a fabric and the combined product has a ratio of 1:2- 1:4, fabric to liquid.
Fabric is shortly thereafter introduced into a sterile receptacle comprising the liquid. The wipes are then cut and folded and packaged into a sealed, waterproof packaging to avoid evaporation or contamination.
According to embodiments, described herein is a wet wipe composition comprising a fabric, and a liquid composition, the liquid composition comprising a cannabinoid and at least one additional active agent selected from the group consisting of a vasoconstrictor and an astringent. Optionally, the composition further comprising an anesthetic. Optionally, the astringent is selected from the group consisting of: witch hazel, calamine and tannic acid. Optionally, the astringent is witch hazel, and is present in an amount of between 10% and 70% of the liquid composition. Optionally, the witch hazel is present in an amount of between 40% and 60% of the liquid composition, optionally, in an amount of 50% of the liquid composition. Optionally, the vasoconstrictor is selected from the group consisting of phenylephrine, ephedrine sulfate, epinephrine, or salts thereof. Optionally, the vacoconstrictor is phenylephrine, and is present in an amount between 0.1% and 1% of the liquid composition. Optionally, phenylephrine is present in an amount between 0.2% and 0.5% of the liquid composition. Optionally, phenylephrine is present in an amount of 0.25% of the liquid composition. Optionally, the anesthetic is selected from the group consisting of: pramoxine, camphor, juniper tar, menthol, diperodon, phenacaine, benzocaine, benzyl alcohol, dibucaine,
dyclonine, lidocaine, and tetracaine, and salts thereof. Optionally, the anesthetic is pramoxine, and is present in an amount between 0.1% and 2% of the liquid composition. Optionally, the pramoxine is present in an amount between 0.5% and 1.51% of the liquid composition. Optionally, the pramoxine is present in an amount of 1% of the liquid composition. Optionally, the cannabinoid is cannabidiol (CBD). Optionally, CBD is present in an amount between 0.01% and 10% of the liquid composition, in an amount between 0.1% and 1% of the liquid composition, in an amount between 0.25% and 0.5% of the liquid composition, or in an amount of 0.35% of the liquid composition. Optionally, the composition further comprises an analgesic or antipruritic agent. Optionally, the analgesic or antipruritic agent is selected from the group consisting of: camphor, juniper tar and menthol. Optionally, the composition further comprises one or more of the following ingredients: water, a solvent, an emulsifier, an emollient, a moisturizer, a pH adjustment agent, a polymer, a humectant, an occlusive agent, a preservative, a thickener, an anti-irritation agent, a conditioning agent, a buffer, a vitamin, an extract, a natural oil, a wax, a penetration enhancer, a peptide, a sugar derivative, a fatty acid, a fatty alcohol, a silicone, a polyethyl-glycol, a fragrance, a pigment, an ester, a triglyceride, a butter, hyaluronic acid, and an absorbing powder. Optionally, the moisturizer is selected from the group consisting of aloe barbadensis leaf juice and panthenol. Optionally, the humectant is glycerin. Optionally, the liquid is an oil in water emulsion. Optionally, the emulsifier is selected from the group consisting of: Acrylates/ C 10-30 alkyl acrylate crosspolymer (Pemulen™ Tr-2); Sodium Acrylates/C 10-30 Alkyl Acrylates Crosspolymers (Cosmedia® SP); Trilaureth-4 Phosphate (Hostaphat® KL 340) and Cetearyl Isononanoate (and) Ceteareth- 20 (and) Cetearyl Alcohol (and) Glyceryl Stearate (and) Glycerin (and) Ceteareth-12 (and) Cetyl Palmitate (Emulgade® CM); C14-22 Alcohols (and) C12-20 Alkyl Glucoside (MONTANOV L); Arachidyl Alcohol (and) Behenyl Alcohol (and) Arachidyl Glucoside (MONTANOV 202); Polyacrylate Crosspolymer-6 (SEPIMAX ZEN); Microcrystalline cellulose and cellulose gum (AVICEL PC 611); Sucrose Palmitate (Sistema PS750-C); Aqua, Sucrose Laurate, Alcohol (Sisterna L70-C); CETEARYL ALCOHOL AND CETETH - 20 PHOSPHATE AND DICETYL PHOSPHAT (CRODAFOS CS20 ACID); Potassium Laureth- 1 Phosphate (Dermalcare® MAP L-213/K); Hydroxy ethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer (and) Isohexadecane (and) Polysorbate 60 (SIMULGEL™ INS 100); Glyceryl Stearate Citrate (and) Polyglyceryl-3 Stearate (and) Hydrogenated Lecithin (Heliofeel™); Ceteareth-25 (and) Disodium Ethylene Dicocamide PEG- 15 Disulfate (CERALUTION ES RSPO-MB); Sorbitan Stearate (SPAN 60); Glyceryl Stearate (and) PEG- 100 Stearate (ARLACEL 165 FL); Polyacrylate Crosspolymer- 11 (Aristoflex® Velvet);
Ammonium Acryloyldimethyltaurate/ Beheneth-25 Methacrylate Crosspolymer (Aristoflex® BLV); Ammonium Acryloyldimethyltaurate/VP Copolymer; Glyceryl Stearate; (Aristoflex® AVC); (Aristoflex® TAC); Ammonium Acryloyldimethyltaurate/ Carboxyethyl Acrylate Crosspolymer (Aristoflex® TAC); Acrylates/C 10-30 Alkyl Acrylate Crosspolymer (Carbopol® Ultrez 20 Polymer); Acrylates Copolymer (Carbopol® Aqua SF-1 Polymer); Lauryl Glucoside (and) Polyglyceryl-2 Dipolyhydroxystearate (and) Glycerin (Eumulgin® VL 75); and CETEARETH-22 (and) PALMETH-2 (EMULPHARMA XL). Optionally, the ratio between fabric and liquid composition is between 1:2 and 1:4. Optionally, the ratio between fabric and liquid composition is 1:3. Further embodiments relate to a method for treatment of hemorrhoids comprising applying to an affect area of a subject in need thereof, a wet wipe as described above. Optionally, the subject suffers from an external hemorrhoid.
In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
Claims
1. A wet wipe composition comprising a fabric, and a liquid composition, the liquid composition comprising a cannabinoid and at least one additional active agent selected from the group consisting of a vasoconstrictor and an astringent.
2. The composition according to claim 1, further comprising an anesthetic.
3. The composition according to claim 1 or 2 wherein the astringent is selected from the group consisting of: witch hazel, calamine and tannic acid.
4. The composition according to claim 3 wherein the astringent is witch hazel, and is present in an amount of between 10% and 70% of the liquid composition.
5. The composition according to claim 4 wherein the witch hazel is present in an amount of between 40% and 60% of the liquid composition.
6. The composition according to claim 5 wherein the witch hazel is present in an amount of 50% of the liquid composition.
7. The composition according to any one of claims 1-6 wherein the vasoconstrictor is selected from the group consisting of phenylephrine, ephedrine sulfate, epinephrine, or salts thereof.
8. The composition according to claim 7 wherein the vacoconstrictor is phenylephrine and is present in an amount between 0.1% and 1% of the liquid composition.
9. The composition according to claim 8 wherein phenylephrine is present in an amount between 0.2% and 0.5% of the liquid composition.
10. The composition according to claim 9 wherein phenylephrine is present in an amount of 0.25% of the liquid composition.
11. The composition according to any one of claims 2 to 10 wherein the anesthetic is selected from the group consisting of: pramoxine, camphor, juniper tar, menthol, diperodon, phenacaine, benzocaine, benzyl alcohol, dibucaine, dyclonine, lidocaine, and tetracaine, and salts thereof.
12. The compositions according to claim 11 wherein the anesthetic is pramoxine, and is present in an amount between 0.1% and 2% of the liquid composition.
13. The compositions according to claim 12 wherein the pramoxine is present in an amount between 0.5% and 1.51% of the liquid composition.
14. The compositions according to claim 13 wherein the pramoxine is present in an amount of 1% of the liquid composition.
15. The composition according to any one of the previous claims wherein the cannabinoid is cannabidiol (CBD).
16. The composition according to claim 15 wherein the CBD is present in an amount between 0.01% and 10% of the liquid composition.
17. The composition according to claim 16 wherein the CBD is present in an amount between 0.1% and 1% of the liquid composition.
18. The composition according to claim 17 wherein the CBD is present in an amount between 0.25% and 0.5% of the liquid composition.
19. The composition according to claim 18 wherein the CBD is present in an amount of 0.35% of the liquid composition.
20. The composition according to any one of the previous claims, further comprising an analgesic or antipruritic agent.
21. The composition according to claim 20 wherein the analgesic or antipruritic agent is selected from the group consisting of: camphor, juniper tar and menthol.
22. The composition according to any one of the previous claims, further comprising one or more of the following ingredients: water, a solvent, an emulsifier, an emollient, a moisturizer, a pH adjustment agent, a polymer, a humectant, an occlusive agent, a preservative, a thickener, an anti-irritation agent, a conditioning agent, a buffer, a vitamin, an extract, a natural oil, a wax, a penetration enhancer, a peptide, a sugar derivative, a fatty acid, a fatty alcohol, a silicone, a polyethyl- glycol, a fragrance, a pigment, an ester, a triglyceride, a butter, hyaluronic acid, and an absorbing powder.
23. The composition according to claim 22 wherein the moisturizer is selected from the group consisting of aloe barbadensis leaf juice and panthenol.
24. The composition according to claim 22 wherein the humectant is glycerin.
25. The composition according to any one of the previous claims, wherein the liquid is an oil in water emulsion.
26. The composition according to claims 22 or 25 wherein the emulsifier is selected from the group consisting of: Acrylates/ C 10-30 alkyl acrylate crosspolymer (Pemulen™ Tr-2); Sodium Acrylates/C 10-30 Alkyl Acrylates Crosspolymers (Cosmedia® SP); Trilaureth-4 Phosphate (Hostaphat® KL 340) and Cetearyl Isononanoate (and) Ceteareth-20 (and) Cetearyl Alcohol (and) Glyceryl Stearate (and) Glycerin (and) Ceteareth-12 (and) Cetyl Palmitate (Emulgade® CM); C 14-22 Alcohols (and) C12-20 Alkyl Glucoside (MONTANOV L); Arachidyl Alcohol
(and) Behenyl Alcohol (and) Arachidyl Glucoside (MONTANOV 202); Polyacrylate Crosspolymer-6 (SEPIMAX ZEN); Microcrystalline cellulose and cellulose gum (AVICEL PC 611); Sucrose Palmitate (Sisterna PS750-C); Aqua, Sucrose Laurate, Alcohol (Sisterna L70-C); CETEARYL ALCOHOL AND CETETH - 20 PHOSPHATE AND DICETYL PHOSPHAT (CRODAFOS CS20 ACID); Potassium Laureth-1 Phosphate (Dermalcare® MAP L-213/K); Hydroxy ethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer (and) Isohexadecane (and) Polysorbate 60 (SIMULGEL™ INS 100); Glyceryl Stearate Citrate (and) Polyglyceryl-3 Stearate (and) Hydrogenated Lecithin (Heliofeel™); Ceteareth-25 (and) Disodium Ethylene Dicocamide PEG- 15 Disulfate (CERALUTION ES RSPO-MB); Sorbitan Stearate (SPAN 60); Glyceryl Stearate (and) PEG-100 Stearate (ARLACEL 165 FL); Polyacrylate Crosspolymer- 11 (Aristoflex® Velvet); Ammonium Acryloyldimethyltaurate/ Beheneth-25 Methacrylate Crosspolymer (Aristoflex® BLV); Ammonium Acryloyldimethyltaurate/VP Copolymer; Glyceryl Stearate; (Aristoflex® AVC); (Aristoflex® TAC); Ammonium Acryloyldimethyltaurate/ Carboxyethyl Acrylate Crosspolymer (Aristoflex® TAC); Acrylates/C 10-30 Alkyl Acrylate Crosspolymer (Carbopol® Ultrez 20 Polymer); Acrylates Copolymer (Carbopol® Aqua SF-1 Polymer); Lauryl Glucoside (and) Polyglyceryl-2 Dipoly hydroxy stearate (and) Glycerin (Eumulgin® VL 75); and CETEARETH-22 (and) PALMETH-2 (EMULPHARMA XL).
27. The composition according to any one of the previous claims, wherein the ratio between fabric and liquid composition is between 1:2 and 1:4.
28. The composition according to claim 27 wherein the ratio between fabric and liquid composition is 1:3.
29. A method for treatment of hemorrhoids comprising applying to an affect area of a subject in need thereof, a wet wipe according to any one of the previous claims.
30. The method according to claim 29 wherein the subject suffers from an external hemorrhoid.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21747149.9A EP4096783A4 (en) | 2020-01-30 | 2021-01-20 | Compositions for hemorrhoid treatment |
US17/795,553 US20230094265A1 (en) | 2020-01-30 | 2021-01-20 | Compositions for hemorrhoid treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062967614P | 2020-01-30 | 2020-01-30 | |
US62/967,614 | 2020-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021152575A1 true WO2021152575A1 (en) | 2021-08-05 |
Family
ID=77078633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2021/050059 WO2021152575A1 (en) | 2020-01-30 | 2021-01-20 | Compositions for hemorrhoid treatment |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230094265A1 (en) |
EP (1) | EP4096783A4 (en) |
WO (1) | WO2021152575A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023034446A1 (en) * | 2021-09-01 | 2023-03-09 | Spinart, LLC | Compositions and methods for promoting and/or maintaining vaginovulval and perianal tissue vitality and tissue health |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015185979A1 (en) * | 2014-06-04 | 2015-12-10 | Peritech Pharma Ltd. | Anorectal compositions comprising an anesthetic as free base and a vasoconstrictor as salt |
CN109908244A (en) | 2019-04-28 | 2019-06-21 | 武汉圣润生物科技有限公司 | A kind of cannabidiol Suppository for treatment of pile and preparation method thereof for treating qi depression to blood stasis |
WO2020097358A1 (en) * | 2018-11-07 | 2020-05-14 | Columbia Care, Llc | Suppository formulations having cannabinoid |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160374958A1 (en) * | 2015-06-23 | 2016-12-29 | Axim Biotechnologies, Inc. | Anti-microbial composition comprising cannabinoids |
US10835504B2 (en) * | 2018-04-18 | 2020-11-17 | G&S Laboratories, Inc. | Compositions to treat anal itch |
IL262050B (en) * | 2018-10-02 | 2020-04-30 | Unv Medicine Ltd | Compositions comprising cbd for treating hemorrhoids |
CN109908033A (en) * | 2019-04-02 | 2019-06-21 | 浙江邦良日用品有限公司 | A Baby Care wet tissue based on CBD oil formula |
CN109820744A (en) * | 2019-04-02 | 2019-05-31 | 浙江邦良日用品有限公司 | A cleaning makeup removing skin care wet tissue based on CBD oil formula |
CN110038070A (en) * | 2019-05-30 | 2019-07-23 | 武汉圣润生物科技有限公司 | A kind of pharmaceutical composition for treating hemorrhoid, preparation method and application |
-
2021
- 2021-01-20 US US17/795,553 patent/US20230094265A1/en active Pending
- 2021-01-20 EP EP21747149.9A patent/EP4096783A4/en active Pending
- 2021-01-20 WO PCT/IL2021/050059 patent/WO2021152575A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015185979A1 (en) * | 2014-06-04 | 2015-12-10 | Peritech Pharma Ltd. | Anorectal compositions comprising an anesthetic as free base and a vasoconstrictor as salt |
WO2020097358A1 (en) * | 2018-11-07 | 2020-05-14 | Columbia Care, Llc | Suppository formulations having cannabinoid |
CN109908244A (en) | 2019-04-28 | 2019-06-21 | 武汉圣润生物科技有限公司 | A kind of cannabidiol Suppository for treatment of pile and preparation method thereof for treating qi depression to blood stasis |
Non-Patent Citations (2)
Title |
---|
See also references of EP4096783A4 |
TROY ET AL.: "Remington: The Science and Practice of Pharmacy", 2006, LIPPINCOTT WILLIAMS & WILKINS |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023034446A1 (en) * | 2021-09-01 | 2023-03-09 | Spinart, LLC | Compositions and methods for promoting and/or maintaining vaginovulval and perianal tissue vitality and tissue health |
Also Published As
Publication number | Publication date |
---|---|
EP4096783A4 (en) | 2023-10-11 |
EP4096783A1 (en) | 2022-12-07 |
US20230094265A1 (en) | 2023-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11844820B2 (en) | Topical formulation and uses thereof | |
US11696909B2 (en) | Pain-relieving topical compositions | |
KR20000029011A (en) | Composition to enhance skin permeation of topical skin agents | |
JP5052558B2 (en) | Gel ointment | |
CN109862787A (en) | Purposes of the cholesterol oxide sulfuric ester (OCS) in treatment inflammatory skin disease and skin lesion | |
CN104994889A (en) | Methods and compositions for improving appearance and formation of scar tissue | |
EP4096783A1 (en) | Compositions for hemorrhoid treatment | |
AU2019329703B2 (en) | Methods and compositions to increase hair growth and/or prevent hair loss | |
WO2021017448A1 (en) | External composition for skin having itching relieving effect | |
EP3461490B1 (en) | Pharmaceutical composition for treating hemorrhoidal disaese | |
TR202009156A2 (en) | Herbal supplement cream that supports wound healing and inflammation reduction | |
JPH11116458A (en) | Composition of preparation for external use for skin | |
KR20210024268A (en) | Cosmetic composition containing centella asiatica extract, ceramide and betula alba juice for relieving skin irritation and reinforcing skin barrier | |
DK181458B1 (en) | Wound treatment composition, use thereof and method for providing said composition | |
WO2018227044A1 (en) | Topical analgesic gel formulations and methods of using them | |
US20230338309A1 (en) | Compositions and methods for topical treatment of vascular conditions | |
EP3871672B1 (en) | Comfreyns, arylnaphthalene lignans that inhibit pro-inflammatory gene expression, and pharmaceutical composition comprising them | |
RU2770422C1 (en) | Pharmaceutical composition in form of hydrogel with venotonic and wound healing action | |
US20230302028A1 (en) | Pain-relieving topical compositions | |
CN114796317A (en) | Herbal comfortable nourishing cream | |
AU2022282563A1 (en) | Composition comprising cannabidiol for application in a body cavity | |
CN105073203A (en) | Methods and compositions for improving appearance and formation of scar tissue | |
GB2473735A (en) | Skin formulation including chamomile and lavender oils |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21747149 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021747149 Country of ref document: EP Effective date: 20220830 |